

BEST AVAILABLE COPY

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : A61K 31/23</p>	<p>A1</p>	<p>(11) International Publication Number: WO 98/19675</p> <p>(43) International Publication Date: 14 May 1998 (14.05.98)</p>		
<table style="width: 100%;"> <tr> <td style="width: 50%; vertical-align: top;"> <p>(21) International Application Number: PCT/US97/20098</p> <p>(22) International Filing Date: 4 November 1997 (04.11.97)</p> <p>(30) Priority Data: 60/030,394 5 November 1996 (05.11.96) US</p> <p>(71) Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION [US/US]; 614 North Walnut Street, P.O. Box 7365, Madison, WI 53707-7365 (US).</p> <p>(72) Inventors: COOK, Mark, E.; 15 Kewaunee Court, Madison, WI 53705 (US). KIM, Sohee; Samik Apt., 7 dong, 511, 313, Dongdaesin 2 Ga, Suh-gu, Pusan (KR). PARIZA, Michael, W.; 7102 Valhalla Trail, Madison, WI 53719 (US). DeVONEY, Danielle; 69 Ponwood Circle, Madison, WI 53717-1179 (US).</p> <p>(74) Agent: BERSON, Bennett, J.; Quarles & Brady, P.O. Box 2113, Madison, WI 53701-2113 (US).</p> </td> <td style="width: 50%; vertical-align: top;"> <p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> </td> </tr> </table>			<p>(21) International Application Number: PCT/US97/20098</p> <p>(22) International Filing Date: 4 November 1997 (04.11.97)</p> <p>(30) Priority Data: 60/030,394 5 November 1996 (05.11.96) US</p> <p>(71) Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION [US/US]; 614 North Walnut Street, P.O. Box 7365, Madison, WI 53707-7365 (US).</p> <p>(72) Inventors: COOK, Mark, E.; 15 Kewaunee Court, Madison, WI 53705 (US). KIM, Sohee; Samik Apt., 7 dong, 511, 313, Dongdaesin 2 Ga, Suh-gu, Pusan (KR). PARIZA, Michael, W.; 7102 Valhalla Trail, Madison, WI 53719 (US). DeVONEY, Danielle; 69 Ponwood Circle, Madison, WI 53717-1179 (US).</p> <p>(74) Agent: BERSON, Bennett, J.; Quarles & Brady, P.O. Box 2113, Madison, WI 53701-2113 (US).</p>	<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(21) International Application Number: PCT/US97/20098</p> <p>(22) International Filing Date: 4 November 1997 (04.11.97)</p> <p>(30) Priority Data: 60/030,394 5 November 1996 (05.11.96) US</p> <p>(71) Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION [US/US]; 614 North Walnut Street, P.O. Box 7365, Madison, WI 53707-7365 (US).</p> <p>(72) Inventors: COOK, Mark, E.; 15 Kewaunee Court, Madison, WI 53705 (US). KIM, Sohee; Samik Apt., 7 dong, 511, 313, Dongdaesin 2 Ga, Suh-gu, Pusan (KR). PARIZA, Michael, W.; 7102 Valhalla Trail, Madison, WI 53719 (US). DeVONEY, Danielle; 69 Ponwood Circle, Madison, WI 53717-1179 (US).</p> <p>(74) Agent: BERSON, Bennett, J.; Quarles & Brady, P.O. Box 2113, Madison, WI 53701-2113 (US).</p>	<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>			
<p>(54) Title: USE OF CONJUGATED LINOLEIC ACID TO ENHANCE NATURAL KILLER LYMPHOCYTE FUNCTION</p> <p>(57) Abstract</p> <p>A method of enhancing the activity of natural killer lymphocytes and a method for increasing the basal level of natural killer activity in an animal include the step of administering orally or parenterally to said animal a safe amount of CLA, said amount being effective to enhance the activity of killer lymphocytes or to enhance the basal activity of killer lymphocytes in the animal.</p>				

BEST AVAILABLE

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

5

USE OF CONJUGATED LINOLEIC ACID TO ENHANCE NATURAL KILLER LYMPHOCYTE FUNCTION

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit under 35 U.S.C.
§119(e) of provisional patent application number 60/030,394,
10 filed November 5, 1996.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

Not applicable.

BACKGROUND OF THE INVENTION

The present application generally relates to methods of
15 treating animals, including humans. More particularly, it
relates to methods of treating animals to enhance the activity
of natural killer lymphocytes.

It is known that the natural killer lymphocytes in
animals, including humans, are capable of disabling or
20 destroying cells which have acquired foreign characteristics,
such as tumor cells or virus-infected cells. Enhancing the
activity of killer lymphocytes also could be effective in
preventing the formation of tumor cells and virus-infected
cells and enhancing the immune defenses of an animal against
25 mutated cells of the animal or pathogen infected cells.

Obviously, it would be advantageous to have a method for
enhancing the activity of natural killer lymphocytes in
animals.

BRIEF SUMMARY OF THE INVENTION

30 It is the object of the present invention to disclose a
method of enhancing the activity of natural killer lymphocytes
in animals.

It is another object of the present invention to disclose
a method for increasing the basal level of natural killer

5 activity in an animal.

We have discovered a method of enhancing the activity of killer lymphocytes in an animal, including a human, which comprises administering to the animal a safe and effective amount of a conjugated linoleic acid, such as 9,11-
10 octadecadienoic acid and 10,12-octadecadienoic acid, or active derivatives thereof, such as non-toxic salts, active esters, such as triglycerides, and mixtures thereof.

The conjugated linoleic acids, their non-toxic salts, active esters, active isomers, active metabolics, and mixtures
15 thereof are referred to herein as "CLA."

It will be apparent to those skilled in the art that the forementioned objects and other advantages may be achieved by the practice of the present invention.

BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS

20 Fig. 1 reports the average number of splenic lymphocytes harvested from the spleens of animals fed either CLA or LA and which additionally were either unstimulated or stimulated with poly-IC to enhance NK activity.

Fig. 2 reports the average number of NK cells per spleen
25 harvested from animals fed either CLA or LA and which additionally were either unstimulated or stimulated with poly-IC to enhance NK activity.

Fig. 3 reports the percent of NK cells in splenic lymphocytes harvested from animals fed either CLA or LA and
30 which additionally were either unstimulated or stimulated with poly-IC to enhance NK activity.

Fig. 4 reports the NK activity of splenic lymphocytes harvested from animals fed either CLA or LA and which additionally were either unstimulated or stimulated with poly-
35 IC to enhance NK activity.

Fig. 5 reports the difference in fold-increase in NK activity after stimulation with poly-IC between animals fed CLA or LA.

5

DETAILED DESCRIPTION OF THE INVENTION

In the preferred method of the present invention for enhancing the activity of killer lymphocytes in an animal, a safe and effective amount of CLA is administered to the animal.

Since CLA is a natural food ingredient and it is relatively non-toxic, the amount of CLA which can be administered is not critical as long as it is enough to be effective.

The methods of the present invention may take several embodiments. In one embodiment, the CLA is administered to an animal in a pharmaceutical or veterinary composition containing a safe and effective dose of the CLA. In another embodiment, the animal is fed a food that has been enriched with CLA.

The animal feeds and pharmaceutical preparations for use in the methods of the present invention are those containing the CLA in combination with a conventional animal feed (e.g. poultry feed), human food supplement, or approved pharmaceutical diluent.

Active forms of CLA include the free conjugated linoleic acids, the active isomers of those acids, non-toxic salts thereof, active esters of those acids, such as the triglycerides, methyl and ethyl esters, and other active chemical derivatives thereof, and mixtures thereof.

The free conjugated linoleic acids (CLA) have been previously isolated from fried meats and described as anti-carcinogens by Y. L. Ha, N. K. Grimm and M. W. Pariza, in Carcinogenesis Vol. 8, No. 12, pp. 1881-1887 (1987). Since then, they have been found in some processed cheese products (Y.L. Ha, N. K. Grimm and M. W. Pariza, in J. Agric. Food Chem., Vol. 37, No. 1, pp. 75-81 (1987)).

The free acid forms of the CLA may be prepared by isomerizing linoleic acid. The non-toxic salts of the free CLA acids may be made by reacting the free acids with a non-toxic base. Natural CLA may also be prepared from linoleic acid by the action of W¹²-cis, W¹¹-transisomerase from a harmless microorganism such as the Rumen bacterium Butyrivibrio fibrisolvens. Harmless microorganisms in the intestinal tracts of rats and other monogastric animals may also convert linoleic

5 acid to CLA (S.F. Chin, W. Liu, K. Albright and M.W. Pariza, 1992, FASEB J.6:Abstract #2665).

The CLA obtained by the practice of the described methods of preparation contains one or more of the 9,11-octadecadienoic acids and/or 10,12-octadecadienoic acids and active isomers
10 thereof. It may be free or bound chemically through ester linkages. The CLA is heat stable and can be used as is, or dried and powdered. The free acids are readily converted into a non-toxic salt, such as the sodium, potassium or calcium salts, by reacting chemically equivalent amounts of the free
15 acid with an alkali hydroxide at a PH of about 8 to 9.

Theoretically, 8 possible geometric isomers of 9,11- and 10,12-octadecadienoic acid (c9,c11; c9,t11; t9,c11; t9,t11; c10,c12; c10,t12; t10,c12 and t10,t12) would form from the isomerization of c9,c12-octadecadienoic acid. As a result of
20 the isomerization, only four isomers (c9,c11; c9,t11; t10,c12; and c10,c12) would be expected. However, of the four isomers, c9,t11- and t10,c12- isomers are predominantly produced during the autoxidation or alkali-isomerization of c9,c12-linoleic acid due to the co-planar characteristics of 5 carbon atoms
25 around a conjugated double-bond and spatial conflict of the resonance radical. The remaining two c,c-isomers are minor contributors.

The relatively higher distribution of the t,t-isomers of 9,11- or 10,12-octadecadienoic acid apparently results from the
30 further stabilization of c9,t11- or t10,c12-geometric isomers, which is thermodynamically preferred, during an extended processing time or long aging period. Additionally the t,t-isomer of 9,11- or 10,12-octadecadienoic acid that was predominantly formed during the isomerization of linoleic acid
35 geometrical isomers (t9,t12-, c9,t12- and t9,c12-octadecadienoic acid) may influence the final ratio of the isomers or the final CLA content in the samples.

Linoleic acid geometrical isomers also influence the distribution of minor contributors (c,c-isomers of 9,11- and
40 10,12-, t9,c11- and c11,t12-octadecadienoic acids). The 11,13-isomer might be produced as a minor product from c9,c12-

5 octadecadienoic acid or from its isomeric forms during processing.

10 The CLA, in addition to being added to an animal's food, can be administered in the form of pharmaceutical or veterinary compositions, such as tablets, capsules, solutions or emulsions to the animal or the humans. The exact amount to be administered, of course, depends upon the form of CLA employed and the route of administration, and the nature of the animal's or human's condition. Generally, the amount of CLA employed as a pharmaceutical will range from about 100 mgm to about 20,000
15 mg of CLA (calculated as the free acids) per day. However, the upper limit of the amount to be employed is not critical because CLA is relatively non-toxic. The amounts of CLA (calculated as the free acids) to be added to food as an additive can range from .01% to 2.0% or more by weight of the
20 food.

The practice of the present invention is further illustrated by the following experiments which were conducted.

The object of the first experiment was to determine if CLA prevented cancerous growth by enhancing immune cell activity
25 (natural killer cells) responsible for destroying tumor cells.

In the first experiment, twenty-four mice were fed zero or 0.5% CLA for 4 weeks. Prior to sacrificing the mice, half of the mice on each dietary treatment were injected with 1 mg/kg body weight of endotoxin or phosphate-buffered saline (PBS).
30 Spleens were harvested from these mice, and lymphocytes were isolated. These lymphocytes were co-cultured with a tumor cell line to assess cytotoxic activity of the natural killer cells in spleen. In mice fed CLA, which had been injected with PBS or endotoxin, there were significant enhancements of natural
35 killer lymphocyte activity. In addition, lymphocytes isolated from normal mice and cultured with CLA also displayed enhanced killer activity against the tumor cell line.

5

Table 1

Natural killer cell cytotoxicity

mice fed 4 weeks
 Target 5×10^4
 Effector Target x 60,20
 3 days cul.

10

Target X 60

	Control (PBS)	Control (LPS)	CLA (PBS)	CLA (LPS)
	19	32.1	24	37.9
	27.2	55.2	50.8	67.3
	30	45.7	48.1	58.3
	31.5	51.3	37.3	66.4
	19.3	54.5	32.9	52.9
	20.6	44	30.6	50.9
mean	24.6	47.13333	37.28333	55.61667
SD	5.147491	7.901195	9.487082	10.02903
SE	2.101455	3.22565	3.873085	4.094333

15

Target X 20

	Control (PBS)	Control (LPS)	CLA (PBS)	CLA (LPS)
	10.3	22	25	23.6
	11.4	25	15.2	25.6
	18.4	21.1	16.8	18.4
	16.5	17.1	16	16.3
	11.1	22.6	17.7	27.3
	17.8	25.5	26.5	26.1
mean	14.25	22.21667	19.53333	22.88333
SD	3.379719	2.773335	4.481691	4.106668
SE	1.379764	1.132209	1.829643	1.67654

Spleen Weight / Body weight

	Control (PBS)	Control (LPS)	CLA (PBS)	CLA (LPS)
	0.003	0.0054	0.0035	0.0045
	0.0017	0.0049	0.0038	0.0061
	0.0025	0.0071	0.0039	0.0064
	0.0025	0.0038	0.0044	0.0058
	0.0028	0.0045	0.0036	0.0065
	0.0024	0.0048	0.0029	0.0057
	0.0034	0.0042	0.0029	0.0041
	0.0025	0.0073	0.003	0.0052
Mean	0.0026	0.00525	0.0035	0.005538
SD	0.000164	0.000428	0.000179	0.000289
SE	0.000464	0.001211	0.000505	0.000817

20

5 The second experiment confirmed the observation of the
first experiment that NK cell activity increased in animals fed
a diet that comprises CLA. At the same time, the second
experiment also demonstrated (1) that basal per-cell NK
activity is higher in a CLA-fed animal than in an LA-fed
10 animal, (2) that the spleen is larger and the number of spleen
cells is higher in a CLA-fed animal than in an LA-fed animal,
and (3) that the proportion of NK cells among splenic
lymphocytes is maintained after consuming CLA.

 Three week old weanling C57BL/6 male mice were housed,
15 four to a cage, under standard conditions. The mice were fed a
powdered diet supplemented with either 0.5% linoleic acid (LA)
or 0.5% conjugated linoleic acid (CLA) for twenty-eight days.
Thirty-six hours before animal sacrifice, one-half of the
animals receiving each dietary treatment were injected
20 peritoneally with one hundred microliters of dilute
polyinosinic-polycytidylic acid (poly-IC), an agent known to
stimulate natural killer (NK) cell activity *in vivo*. Splenic
lymphocytes were isolated from spleen homogenates by gradient
centrifugation. The splenic lymphocytes were counted and three
25 serial dilutions were prepared. Spleen samples were not
pooled.

 The average number of lymphocyte cells harvested per
spleen (Fig. 1) was significantly higher in CLA-fed mice than
in LA-fed mice. The number of lymphocyte cells per spleen
30 appeared to be largely independent of whether the mice were
stimulated to increase NK activity.

 The average number of NK cells per spleen (Fig. 2) was
also significantly higher in CLA-fed mice than in LA-fed mice.
Again, the number of NK cells isolated per spleen appeared to
35 be largely independent of whether the mice were stimulated to
increase NK activity.

 The percent of NK cells among splenic lymphocytes (Fig. 3)
was fairly constant and appeared to be unaffected either by
stimulation with poly-IC or by the presence of CLA or LA in the
40 diet.

5 NK activity in the isolated spleen cells was assessed in a standard NK assay run in triplicate for each animal using the YAC-1 lymphoma cell line as a target. YAC-1 cells (commercially available from the American Type Culture Collection, Rockville, MD (Accession Number TIB-160)) were co-cultured for four hours in 96-well plates with splenic lymphocytes at 3 effector-to-target (E:T) cell ratios in the range of 5 to 35. To quantify the cells that remained alive at the end of the four hour assay, the tetrazolium dye MTT was added and after four more hours of incubation a formamide-based stopping solution was added. The plates were incubated overnight for color development. Absorbance at 562 nanometers was measured for each well. Associated blanks and controls were run on each plate.

20 From the absorbance data, a regression curve was created to relate NK activity to E:T ratio. The average expected NK activity at the E:T ratio of 11.0 was determined for each diet/injection group and standard deviations and standard errors were calculated.

25 Fig. 4 presents NK activity data normalized to reflect the same number of cells in each well. The left side of Fig. 4 depicts results for animals that were not stimulated with poly-IC, while the right side reports results for poly-IC stimulated animals. Unstimulated animals (Fig. 4, left) fed a diet supplemented with 0.5% CLA exhibit increased NK activity in splenic lymphocytes relative to animals fed a comparable amount of LA.

30 Poly-IC-stimulated mice (Fig. 4, right) fed with LA appear to have a higher level of NK activity than splenic lymphocytes from CLA-fed mice. However, when the basal level of NK activity (in the PBS injected mice) is compared against the stimulated activity in poly-IC stimulated mice, for each diet, LA fed mice have a 1.87 fold increase in NK activity whereas CLA fed mice have a 1.30 fold increase (Fig. 5).

40 Without further analysis, these data could mislead one to believe that LA has a greater effect than CLA. However, a more proper analysis is that mice fed with CLA have a higher basal

5 level of NK activity than mice fed with LA and achieve a high
level of NK activity in stimulated mice with a lower overall
increase in activity. It is the higher basal level of NK
activity in CLA-fed mice that is of particular interest because
it maintains the surveillance function of NK cells without
10 overstimulating the immune system.

This increased basal level activity comes about not only
by virtue of increased activity per cell, but also from the
observation made here that CLA ingestion increases both the
size of the spleen and the number of cells it contains. Thus,
15 an animal fed with CLA is better equipped to deal with immune
challenges than an animal that has not been fed CLA and which
has a lower basal level of natural killer cell activity.

A third important component of this aspect of the
invention is that a proportionally constant level of NK cell
20 found in animals fed CLA or not fed CLA. It would not have
been predictable that the NK cells would be maintained, as it
is known that various treatments can affect subpopulations of
immune system cells. It would be, for example, unacceptable
for the cells to have an acceptably high activity, but for the
25 cells to be present in such low number as to be immunologically
irrelevant. This can have important therapeutic ramifications
in that it is clear that, after consuming CLA, animals maintain
a number of cells in the NK subpopulation that is sufficiently
high to permit immune surveillance without placing the immune
30 system of the animal into an overstimulated (hyperactive)
state. Since control-fed mice undergo a much greater
proliferative response than CLA-fed mice upon immune challenge
(endo or poly IC), the relative requirement for hyperimmunity
is likely to have adverse effects on other physiological
35 function in non-CLA-fed mice. CLA-fed animals naturally have
higher numbers of NK cells, hence those animals do not have to
go through a hyperactive immune process to reach cell numbers
sufficient for immune defense. Moreover, it is shown herein
that the NK cells themselves have high NK activity on a per-
40 cell basis.

5 In summary, then, the applicants have herein shown that a
method for enhancing a basal level of natural killer cell
activity in an animal, includes the step of administering a
safe amount of CLA to the animal, the amount being effective to
increase the basal level of NK activity over the level observed
10 in animals not fed CLA.

 It will be readily apparent to those skilled in the art
that a number of modifications or changes may be made without
departing from the spirit and scope of the present invention.

CLAIMS

We claim:

- 5 1. A method of maintaining or enhancing the activity of killer lymphocytes in an animal, said method comprising administering orally or parenterally to said animal a safe amount of CLA, said amount being effective to enhance the activity of killer lymphocytes.
2. The method as claimed in Claim 1 wherein the CLA is administered orally to the animal in a food.
3. The method as claimed in Claim 1 wherein the CLA is administered as a non-toxic salt of CLA, as an active ester of CLA or as a mixture thereof.
4. A method of increasing basal activity of killer lymphocytes in an animal, said method comprising administering orally or parenterally to said animal a safe amount of CLA, said amount being effective to enhance the basal activity of killer lymphocytes in the animal.
5. The method as claimed in Claim 4 wherein the CLA is administered orally to the animal in a food.
6. The method as claimed in Claim 4 wherein the CLA is administered as a non-toxic salt of CLA, as an active ester of CLA or as a mixture thereof.
7. A method of preventing a hyperactive killer cell response following immune challenge, said method comprising administering orally or parenterally to said animal a safe amount of CLA, said amount being effective to enhance the basal activity of killer lymphocytes in the animal.
8. The method as claimed in Claim 7 wherein the CLA is administered orally to the animal in a food.


9. The method as claimed in Claim 7 wherein the CLA is administered as a non-toxic salt of CLA, as an active ester of CLA or as a mixture thereof.

10. A method of maintaining or enhancing anti-tumor cell activity of killer lymphocytes in an animal, said method comprising administering orally or parenterally to said animal a safe amount of CLA, said amount being effective to enhance the activity of killer lymphocytes.

11. The method as claimed in Claim 10 wherein the CLA is administered orally to the animal in a food.

12. The method as claimed in Claim 10 wherein the CLA is administered as a non-toxic salt of CLA, as an active ester of CLA or as a mixture thereof.

Total Splenic Lymphocytes



Injection

FIG 1




FIG 2




FIG 3

Natural Killer Cell Activity




FIG 4

Increase in NK Activity




FIG 5

INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 A61K31/23		International Application No PCT/US 97/20098		
According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED				
Minimum documentation searched (classification system followed by classification symbols) IPC 6 A61K				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
P, X	M.W WONG ET AL.: "Effects of dietary conjugated linoleic acid on lymphocyte function and growth of mammary tumors in mice." ANTICANCER RES., vol. 17, no. 2A, 1997, pages 987-993, XP002056186 see the whole document	1,2,4,5, 7,8,10, 11		
A	M. PARIZA ET AL.: "Chemoprevention by CLA: a role for prostaglandins." PROC. ANNU. MEET. AM. ASSOC. CANCER RES., vol. 34, 1993, page A3315 XP002056187			
<input type="checkbox"/> Further documents are listed in the continuation of box C. <input type="checkbox"/> Patent family members are listed in annex.				
* Special categories of cited documents:				
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top;"> "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed </td> <td style="width: 50%; vertical-align: top;"> "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family </td> </tr> </table>			"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family			
Date of the actual completion of the international search <div style="text-align: center; font-weight: bold;">18 February 1998</div>		Date of mailing of the international search report <div style="text-align: center; font-weight: bold;">12/03/1998</div>		
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer <div style="text-align: center; font-weight: bold;">Klaver, T</div>		

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☒ **FADED TEXT OR DRAWING**

☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)